Regado Biosciences, which is developing drugs to control bleeding, has raised $51 million in new financing, including backing from Triangle-based Aurora Funds.
Regado is based in New Jersey but maintains its research and development lab in Durham.
The firm landed a new investor, RusnanoMedInvest, which is part of a Russian government-owned investment firm called Rusnano.
Other investors included Baxter Ventures, which also is a new investor, along with previous backers Edmond de Rothschild Investment Partners, Domain Associates, Quaker Partners, Aurora and Caxton Advantage Life Sciences Fund.
“We are proud to say this financing is among the largest private rounds to be completed in 2012,” said David J. Mazzo, Regado’s chief executive officer.
Funds will be used to develop one treatment in a Phase 3 clinical trial called REG1.
REG1 targets blood clotting and would be used in coronary intervention. REG1 could be used in open heart surgery.
Regado, which is developing technology from Duke University, closed on a “D” round of financing totaling just over $21.5 million in July of 2011.. Regado has been raising the funding since December 2009.
Regado’s DNA-based system could present an alternative to such drugs as Heparin and Coumadin, which help prevent heart attacks, strokes and deep-vein thrombosis but also increase the risk of uncontrolled bleeding.
Regado raised $23 million in 2007 and $20 million in 2005.
